Published: 3/5/2024
(Akron, OH) – March 5, 2024 - Smithers, a leading provider of testing, consulting, information, and compliance services, recently appointed Dr. Frederick Strathmann, Ph.D. as the new Clinical Laboratory Improvement Amendments (CLIA) director of Smithers Pharmaceutical Development Services. Strathmann succeeds Dr. Janine Cook, Ph.D., retiring after more than 25 years of distinguished service in the healthcare and pharmaceutical industry.
Strathmann brings over 15 years of extensive experience in laboratory medicine, having held several prestigious positions throughout his career. His roles have included Assistant Professor of Pathology & Laboratory Medicine, Medical Director of Toxicology, Scientific Director of Mass Spectrometry, and Senior Vice President of Operations and Research & Development. Strathmann’s expertise spans both hospital and national reference laboratory environments, making him a valuable addition to the Smithers team.
Board certified by the American Board of Clinical Chemistry in both Clinical Chemistry and Toxicological Chemistry, Strathmann also holds a New York Certificate of Qualification (CoQ) in numerous categories. His qualifications extend to serving as a CLIA Laboratory Director for High Complexity Testing, underscoring his capability to lead Smithers’ laboratory services to new heights of excellence and innovation.
Christina Satterwhite Ph.D. President, at Smithers Pharmaceutical Development Services Division, said “We are delighted to have Strathmann as our new CLIA director at our division. With his impressive track record of over 15 years in various prestigious roles, we are confident that our CLIA-certified laboratories will reach new heights, furthering our commitment to advancing the pharmaceutical development of our customers.”
“We are thrilled to welcome Dr. Frederick Strathmann to our team,” said Ira DuBey, Ph.D. Chief Commercial Officer, at Smithers Pharmaceutical Development Services Division. “His impressive background and leadership in laboratory medicine will be instrumental in advancing our mission to provide cutting-edge pharmaceutical development services. We are confident that under his direction, our CLIA-certified laboratories will continue to set industry standards for quality and reliability.”
Strathmann’s appointment comes as Janine Cook, Ph.D., the outgoing CLIA Director, retires following a remarkable career. Cook has been instrumental in shaping the laboratory services at Smithers, and her contributions have left an indelible mark on the industry. Smithers extends its deepest gratitude to Cook for her dedication and leadership.
Located in Gaithersburg, Maryland, and Ewing, New Jersey Smithers Pharmaceutical Development Services Division, are GCLP-compliant facilities and CLIA-certified laboratories, that support the development of large molecule therapeutics from discovery through phase IV, with expertise in bioassays and ultra-sensitivity ligand-binding assays. Our services focus on development, validation, and sample analysis for PK/TK, ADA, bioassays, and fit-for-purpose biomarker studies. Smithers supports the Development of biologics/monoclonal & polyclonal antibodies, bi-specific antibodies, CAR-T, TCR, and Biosimilars. Additionally, Smithers supports Cell and Gene Therapy Studies.
For more information about our CRO services, contact Frederick Strathmann at Frederick.strathmann@smithers.com or call (585) 301-6649.
.
For more information about Smithers, please visit https://www.smithers.com/
###
About Smithers:
Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services. With laboratories and operations in North America, Europe, and Asia, Smithers supports customers in the transportation, life science, packaging, materials, components, consumer, cannabis, dry commodities, and energy industries. Smithers delivers accurate data, on time, with high touch, by integrating science, technology, and business expertise, so customers can innovate with confidence.